Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients

• DOI: 10.1007/s00262-021-02961-0
• Publication Date: 2021-06-12T21:02:44Z
• Authors: Brigitte Dréno; Amir Khammari; Agnès Fortun; Virginie Vignard; Soraya Saiagh; Tiffany Beauvais; Nicolas Jouand; Sylvain Bercegay; Sylvain Simon; François Lang; Nathalie Labarrière
• Keywords: Adoptive Cell Transfer

Abstract Adoptive cell transfer (ACT) of tumor-specific T lymphocytes represents a relevant therapeutic strategy to treat metastatic melanoma patients. Ideal T-cells should combine tumor specificity and reactivity with survival in vivo, while avoiding autoimmune side effects. Here we report results from Phase I/II clinical trial (NCT02424916, performed between 2015 2018) which 6 HLA-A2 patients received autologous antigen-specific produced PBMC, after peptide stimulation vitro, followed by sorting HLA-peptide multimers amplification. Each patient combination Melan-A MELOE-1 polyclonal specific T-cells, whose anti-tumor were checked prior injection, subcutaneous IL-2. Transferred also characterized terms functional avidity, diversity phenotype their blood persistence was evaluated. An increase detected the all at day 1 progressively disappeared 7 onwards. No serious adverse events occurred this ACT. Clinically, five progressed one experienced partial response following therapy. infused diverse, high proportion co-expressing PD-1 TIGIT but few other exhaustion markers. In conclusion, demonstrated feasibility safety ACT multimer-sorted cells The efficacy such could be further enhanced selection highly reactive based on co-expression, ICI, as anti-PD-1.